As described in the STAR Methods section, the validation cohort 1 composed of 65 patients with EGFR-TKI-resistant, EGFR-mutated NSCLC from three different cancer centers and the validation cohort 2 composed of 140 patients pooled together from Hunan Cancer Hospital who had NSCLCs that lacked actionable genetic mutations and received ICI-based regimens as first-line therapy in the real-world setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.